Ten-Year Outcomes for Pathologic Node-Positive Patients Treated in RTOG 75-06
| Autor: | John A Parsons, John D Earle, Roger W Byhardt, M.D. Gerald E. Hanks, Bahman Emami, Anthony H Russell, Philip Rubin, William Sause, Jan Buzydlowski, Miljenko V. Pilepich |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Time Factors medicine.medical_treatment Urology Gleason Score 6 Disease-Free Survival Prostate cancer Clinical endpoint medicine Humans Radiology Nuclear Medicine and imaging Stage (cooking) Survival analysis Radiation business.industry Prostatic Neoplasms Cancer Middle Aged Prostate-Specific Antigen medicine.disease Surgery Radiation therapy Prostate-specific antigen Treatment Outcome Oncology Lymphatic Metastasis Multivariate Analysis business Follow-Up Studies |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 40:765-768 |
| ISSN: | 0360-3016 |
| Popis: | Purpose: This study was conducted to see what fraction of prostate cancer patients with biopsy-proven nodes are free of cancer 10 years after radiation treatment. Methods and Materials: RTOG protocol #75-06 included 90 patients with biopsy-proven pelvic nodal involvement treated with radiation. They have been continuously follow-up since treatment. When feasible, current prostate-specific antigen (PSA) levels have been solicited from patients clinically cancer-free (no evidence of disease, NED) at 10 years, to confirm cure. Results: The 10-year survival was 29%, the 10-year clinical NED survival 7%. PSA levels were obtained in 2 of 5 10-year clinical NED patients, they were both less than 0.8 ng/ml. The 2 proven cures were both clinical stage T-3, Gleason Score 6 and 8, and had 2 and 1 positive nodes, respectively. Multivariate analysis showed Gleason sum was significantly associated with clinical survival without disease. Conclusion: A small fraction of node-positive patients are cured at 10-year follow-up by radiation therapy (2 of 90 with PSA +3 of 90 by clinical endpoints). Innovative treatment programs should be directed at node-positive patients in an effort to improve the fraction cured. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|